Document is current
Any future updates will be listed below
-
Authors
Ouyang, Wenlu
Chen, Yuchen https://orcid.org/0000-0001-8558-3062
Tan, Tao
Song, Yujing https://orcid.org/0000-0003-1448-3069
Dong, Tao
Yu, Xin https://orcid.org/0009-0001-2847-2590
Lee, Kyung Eun
Zhou, Xinyu
Tetz, Zoe
Go, Sophia
Zeng, Xindi
Shao, Liujiazi
Quan, Chao
Zhao, Ting https://orcid.org/0009-0004-0768-4764
Tian, Yuzi
Kurabayashi, Katsuo https://orcid.org/0000-0002-9613-3590
Jin, Hua
Ma, Jichun https://orcid.org/0000-0002-9617-5141
Qin, Jingdong
Williams, Brandon
Li, Qingtian
Zhu, Gui-dong https://orcid.org/0009-0003-0097-3240
Alam, Hasan B. https://orcid.org/0000-0002-1024-5226
Stringer, Kathleen A. https://orcid.org/0000-0003-0238-7774
Li, Yongqing https://orcid.org/0000-0001-8266-924X
Ma, Jianjie https://orcid.org/0009-0002-1730-7933
-
Funding
Funding for this research was provided by:
NIH
- License Information
-
More Information
Article History
Received: 13 January 2025
Accepted: 29 July 2025
First Online: 12 August 2025
Competing interests
: Patent application related to the hCitH3-mAb technology was filed by University of Virginia Patent Foundation, The Reagents of University of Michigan and HTIC, Inc. J.M., Y.L. and T.T. are co-founders of HTIC that develops hCitH3-mAb for immune modulation applications. The remaining authors declare no competing interests.
